Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination

• Karina Soboleva,
• Nirmal Kumar Shankar,
• Madhavi Yadavalli,
• Cátia Ferreira,
• Nadia Foskett,
• Kert Putsepp,
• Lisa Beth Ferstenberg,
• Magnus Nord,
• Hugo Gomes da Silva,
• Prakash Bhuyan

Affiliations

Karina Soboleva

Clinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA

Nirmal Kumar Shankar

Patient Safety, Chief Medical Office, R&D, AstraZeneca India, Bangalore, India

Madhavi Yadavalli

Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA

Cátia Ferreira

BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA

Nadia Foskett

BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

Kert Putsepp

BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA

Lisa Beth Ferstenberg

Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA

Magnus Nord

Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden

Hugo Gomes da Silva

BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

Prakash Bhuyan

Clinical Development, Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA